Financials data is unavailable for this security.
View more
Year on year Aurobindo Pharma Ltd grew revenues 16.68% from 248.55bn to 290.02bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 64.62% net income growth from 19.28bn to 31.73bn.
| Gross margin | 58.76% |
|---|---|
| Net profit margin | 11.83% |
| Operating margin | 15.80% |
| Return on assets | 7.79% |
|---|---|
| Return on equity | 12.13% |
| Return on investment | 11.08% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Aurobindo Pharma Ltd fell by 10.07bn. However, the company earned 24.35bn from its operations for a Cash Flow Margin of 8.39%. In addition the company generated 8.00bn cash from financing while 42.56bn was spent on investing.
| Cash flow per share | 87.56 |
|---|---|
| Price/Cash flow per share | 13.89 |
| Book value per share | 531.65 |
|---|---|
| Tangible book value per share | 462.63 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.83 |
|---|---|
| Quick ratio | 1.10 |
| Total debt/total equity | 0.2729 |
|---|---|
| Total debt/total capital | 0.2144 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 50.00% and 64.62%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.66% |
|---|---|
| Div growth rate (5 year) | 12.47% |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 6.06 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 54.83 |
More ▼
